{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:24:11Z","timestamp":1777407851883,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.canlet.2021.09.017","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T11:53:57Z","timestamp":1632225237000},"page":"72-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Dual mTORC1\/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth"],"prefix":"10.1016","volume":"523","author":[{"given":"Ruyu","family":"Pi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houhui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianqi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuquan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6513-6422","authenticated-orcid":false,"given":"Xiawei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.canlet.2021.09.017_bib1","first-page":"280","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"Ca-a Cancer Journal for Clinicians"},{"key":"10.1016\/j.canlet.2021.09.017_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nature Reviews Disease Primers"},{"issue":"9","key":"10.1016\/j.canlet.2021.09.017_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10090302","article-title":"Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment","volume":"10","author":"Drakes","year":"2018","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.canlet.2021.09.017_bib4","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2021.09.017_bib5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3389\/fimmu.2019.01273","article-title":"Myeloid derived suppressor cells: Key drivers of immunosuppression in ovarian cancer","volume":"10","author":"Baert","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.canlet.2021.09.017_bib6","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1158\/0008-5472.CAN-19-2558","article-title":"Murine oviductal high-grade serous carcinomas mirror the genomic alterations, gene expression profiles, and immune microenvironment of their human counterparts","volume":"80","author":"McCool","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2021.09.017_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.canlet.2021.09.017_bib8","article-title":"The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival","volume":"7","author":"Santegoets","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2021.09.017_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00691","article-title":"Clinical relevance and immunosuppressive pattern of circulating and infiltrating subsets of myeloid-derived suppressor cells (MDSCs) in epithelial ovarian cancer","volume":"10","author":"Okla","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.canlet.2021.09.017_bib10","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","article-title":"mTOR signalling and cellular metabolism are mutual determinants in cancer","volume":"18","author":"Mossmann","year":"2018","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2021.09.017_bib11","doi-asserted-by":"crossref","first-page":"4809751","DOI":"10.1155\/2017\/4809751","article-title":"A review of mTOR pathway inhibitors in gynecologic cancer","volume":"2017","author":"de Melo","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.canlet.2021.09.017_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","article-title":"Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance","volume":"59","author":"Ediriweera","year":"2019","journal-title":"Semin. Canc. Biol."},{"issue":"2","key":"10.1016\/j.canlet.2021.09.017_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2021.09.017_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2010.12.364","article-title":"Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer","volume":"121","author":"No","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2021.09.017_bib15","first-page":"3725","article-title":"Clinical associations between ASCT2 and pmTOR in the pathogenesis and prognosis of epithelial ovarian cancer","volume":"40","author":"Guo","year":"2018","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.canlet.2021.09.017_bib16","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/01443615.2018.1534091","article-title":"The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer","volume":"39","author":"Alabdullah","year":"2019","journal-title":"J. Obstet. Gynaecol."},{"issue":"6","key":"10.1016\/j.canlet.2021.09.017_bib17","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/1535-7163.MCT-11-0723","article-title":"Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications","volume":"11","author":"Carlos Montero","year":"2012","journal-title":"Mol. Canc. Therapeut."},{"issue":"2","key":"10.1016\/j.canlet.2021.09.017_bib18","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.canlet.2014.11.012","article-title":"Pre-clinical evaluation of AZD-2014, a novel mTORC1\/2 dual inhibitor, against renal cell carcinoma","volume":"357","author":"Zheng","year":"2015","journal-title":"Canc. Lett."},{"issue":"9","key":"10.1016\/j.canlet.2021.09.017_bib19","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.21873\/anticanres.13668","article-title":"mTORC1\/2 inhibitor served as a more ideal agent against the growth of mouse lymphocytic leukemia both in vitro and in vivo","volume":"39","author":"Liao","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2021.09.017_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01570","article-title":"EI24 inhibits cell proliferation and drug resistance of esophageal squamous cell carcinoma","volume":"10","author":"Duan","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.canlet.2021.09.017_bib21","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.immuni.2010.05.010","article-title":"Tumor-induced tolerance and immune suppression depend on the C\/EBPbeta transcription factor","volume":"32","author":"Marigo","year":"2010","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.canlet.2021.09.017_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2015.02.003","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in ovarian cancer","volume":"137","author":"Mabuchi","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2021.09.017_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.09.017_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2020.03.013","article-title":"Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer","volume":"479","author":"Takeyama","year":"2020","journal-title":"Canc. Lett."},{"issue":"12","key":"10.1016\/j.canlet.2021.09.017_bib25","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1158\/1078-0432.CCR-14-2777","article-title":"The ovarian cancer chemokine landscape is conducive to homing of vaccine-primed and CD3\/CD28-costimulated T cells prepared for adoptive therapy","volume":"21","author":"Zsiros","year":"2015","journal-title":"Clin. Canc. Res. : an official journal of the American Association for Cancer Research"},{"issue":"2","key":"10.1016\/j.canlet.2021.09.017_bib26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4048\/jbc.2020.23.e26","article-title":"Myeloid-derived suppressor cells recruited by chemokine (C-C motif) ligand 3 promote the progression of breast cancer via phosphoinositide 3-kinase-protein kinase B-mammalian target of rapamycin signaling","volume":"23","author":"Luo","year":"2020","journal-title":"J Breast Cancer"},{"issue":"6","key":"10.1016\/j.canlet.2021.09.017_bib27","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/bjc.2014.55","article-title":"Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity","volume":"110","author":"Gooden","year":"2014","journal-title":"Br. J. Canc."},{"issue":"2","key":"10.1016\/j.canlet.2021.09.017_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000949","article-title":"IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma","volume":"8","author":"Weber","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.canlet.2021.09.017_bib29","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/mc.22419","article-title":"CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway","volume":"55","author":"Wang","year":"2016","journal-title":"Mol. Carcinog."},{"issue":"9","key":"10.1016\/j.canlet.2021.09.017_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075455","article-title":"The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells","volume":"8","author":"Im-aram","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2021.09.017_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-020-02628-2","article-title":"The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer","author":"Komura","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.canlet.2021.09.017_bib32","article-title":"Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes\/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1","volume":"18","author":"Okla","year":"2020","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.canlet.2021.09.017_bib33","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ncb3355","article-title":"Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation","volume":"18","author":"Welte","year":"2016","journal-title":"Nat. Cell Biol."},{"issue":"15","key":"10.1016\/j.canlet.2021.09.017_bib34","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/onc.2014.143","article-title":"Activation of mTOR pathway in myeloid-derived suppressor cells stimulates cancer cell proliferation and metastasis in lal(-\/-) mice","volume":"34","author":"Zhao","year":"2015","journal-title":"Oncogene"},{"issue":"17","key":"10.1016\/j.canlet.2021.09.017_bib35","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1158\/0008-5472.CAN-20-0024","article-title":"Palmitoylated proteins on AML-derived extracellular vesicles promote myeloid-derived suppressor cell differentiation via TLR2\/akt\/mTOR signaling","volume":"80","author":"Tohumeken","year":"2020","journal-title":"Canc. Res."},{"issue":"3","key":"10.1016\/j.canlet.2021.09.017_bib36","doi-asserted-by":"crossref","first-page":"e2695","DOI":"10.1038\/cddis.2017.86","article-title":"The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury","volume":"8","author":"Zhang","year":"2017","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.canlet.2021.09.017_bib37","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1189\/jlb.0913473","article-title":"mTOR limits the recruitment of CD11b(+)Gr1(+)Ly6C(high) myeloid-derived suppressor cells in protecting against murine immunological hepatic injury","volume":"95","author":"Zhang","year":"2014","journal-title":"J. Leukoc. Biol."},{"issue":"2","key":"10.1016\/j.canlet.2021.09.017_bib38","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/jcp.27032","article-title":"mTOR inhibitor INK128 attenuates dextran sodium sulfate-induced colitis by promotion of MDSCs on Treg cell expansion","volume":"234","author":"Shi","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"7754","key":"10.1016\/j.canlet.2021.09.017_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","article-title":"Fatty acid transport protein 2 reprograms neutrophils in cancer","volume":"569","author":"Veglia","year":"2019","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.canlet.2021.09.017_bib40","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jamaoncol.2019.2526","article-title":"Fulvestrant plus Vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor-positive metastatic breast cancer the MANTA phase 2 randomized clinical trial","volume":"5","author":"Schmid","year":"2019","journal-title":"Jama Oncology"},{"issue":"11","key":"10.1016\/j.canlet.2021.09.017_bib41","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1158\/1535-7163.MCT-18-0183","article-title":"Combined inhibition of PI3K beta and mTOR inhibits growth of PTEN-null tumors","volume":"17","author":"Lynch","year":"2018","journal-title":"Mol. Canc. Therapeut."},{"issue":"4","key":"10.1016\/j.canlet.2021.09.017_bib42","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s13402-018-0380-x","article-title":"Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma","volume":"41","author":"Milosevic","year":"2018","journal-title":"Cell. Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2021.09.017_bib43","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/annonc\/mdy245","article-title":"Vistusertib (dual m-TORC1\/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer","volume":"29","author":"Basu","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2021.09.017_bib44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/annonc\/mdz250.001","article-title":"OCTOPUS: a randomised, multi-centre phase II umbrella trial of weekly paclitaxel plus\/- novel agents in platinum-resistant ovarian cancer: Vistusertib","volume":"30","author":"Banerjee","year":"2019","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2021.09.017_bib45","first-page":"17","article-title":"Highlights in ovarian cancer from the 2016 ESMO congress: commentary","volume":"14","author":"Mirza","year":"2016","journal-title":"Clin. Adv. Hematol. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352100464X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352100464X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:58:41Z","timestamp":1759593521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352100464X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":45,"alternative-id":["S030438352100464X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.09.017","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual mTORC1\/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}